Concord Healthcare Group Co., Ltd. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 2453 環境、社會及管治報告 2024 | 關於本報告 | 2 | | --- | --- | | 董事長致辭 | 3 | | 1.1 董事會聲明 4 | | --- | | 1.2 ESG 管治架構 4 | | 1.3 利益相關方溝通 4 | | 1.4 重要性議題分析 6 | | 2.1 排放管理 7 | | --- | | 2.2 資源管理 11 | | 2.3 環境績效 13 | | 2.4 應對氣候變化 15 | | 2.5 環境目標 19 | | 3.1 服務質量與醫療安全 20 | | --- | | 3.2 創新研發與知識產權管理 28 | | 3.3 隱私保護與信息安全 33 | | 3.4 廣告與標識管理 37 | | 4.1 僱傭與勞工管理 39 | | --- | | 4.2 健康與安全 46 | | 4.3 發展與培訓 49 | | | | 關於本報告 本報告是美中嘉和醫學技術發展集團股份有限公司（以下簡稱「美中嘉和」 ...

Demographics and Market Demand - By the end of 2024, the population aged 60 and above in China is expected to exceed 310 million, with 90 million in the younger elderly group (60-65 years), indicating a significant demand for early cancer screening and precision treatment[8]. - The number of new cancer cases in China is significantly increasing, driven by aging population and chronic disease prevalence, creating new demands for cancer prevention and treatment[41]. Company Operations and Expansion - The company has been approved to operate 8 new proton therapy devices, positioning itself as a leading provider in the market, responding to the national policy encouraging social medical services[9]. - The Guangzhou Proton Center, operational by December 2024, will provide treatment for patients aged 4 to 75, covering high-incidence cancers such as head and neck tumors[10]. - The company is collaborating with county hospitals to establish cooperative centers, providing remote planning and MDT consultation services, enhancing grassroots medical capabilities[11]. - The company aims to penetrate second and third-tier cities by offering standardized oncology department solutions, with a contract signed with Shenmu City Hospital[14]. - The company is expanding internationally by offering customized packages for high-incidence cancers in Southeast Asia and establishing a cross-border medical payment system[14]. - The company is focusing on domestic production of proton auxiliary equipment to reduce operational costs and enhance technological autonomy[12]. - The company is leveraging AI and 5G technologies to empower grassroots medical networks, promoting early cancer screening and treatment accessibility[8]. - The group has established four offline self-operated medical institutions focused on high-end oncology medical services, primarily located in Guangzhou and Shanghai[22]. - The Guangzhou Taihe Cancer Hospital, with a planned total construction area of over 100,000 square meters, is set to provide advanced proton therapy services, marking a significant milestone in high-end medical services in South China[23]. - The Shanghai Taihe Cheng Cancer Hospital, under construction, will cover nearly 160,000 square meters and aims to provide precision radiotherapy services, enhancing competitiveness in the high-end medical service market[24]. - The group has launched a light asset business model for medical equipment, software, and related services, targeting hospitals in second and third-tier cities to improve radiation therapy and imaging diagnosis capabilities[26]. - The group aims to deepen cooperation with top international medical institutions to maintain leadership in oncology treatment technology[18]. - The group aims to optimize regional layout by penetrating second and third-tier cities and establishing international cancer treatment centers[42]. Financial Performance - Revenue decreased by 27.9% from RMB 538.7 million for the year ending December 31, 2023, to RMB 388.3 million for the year ending December 31, 2024[21]. - Gross loss increased by 3.3% from RMB 65.1 million for the year ending December 31, 2023, to RMB 67.2 million for the year ending December 31, 2024[21]. - Net loss increased by 13.7% from RMB 426.4 million for the year ending December 31, 2023, to RMB 484.8 million for the year ending December 31, 2024[21]. - Adjusted net loss increased by 5.5% from RMB 420.6 million for the year ending December 31, 2023, to RMB 443.9 million for the year ending December 31, 2024[21]. - Hospital business revenue fell by 15.1% from RMB 320.0 million in 2023 to RMB 271.6 million in 2024[50]. - Revenue from medical equipment, software, and related services dropped by 46.6% from RMB 218.7 million in 2023 to RMB 116.7 million in 2024[50]. - Sales and installation of medical equipment and software revenue decreased by 44.3% from RMB 178.3 million in 2023 to RMB 99.3 million in 2024[50]. - Total cost of sales reduced by 24.5% from RMB 603.7 million in 2023 to RMB 455.6 million in 2024[52]. - Employee benefits expenses decreased from RMB 164.9 million in 2023 to RMB 112.8 million in 2024, representing 24.8% of total sales costs[53]. - Management and technical support revenue fell by 69.9% from RMB 23.1 million in 2023 to RMB 7.0 million in 2024[54]. - Operating lease revenue decreased by 39.1% from RMB 17.2 million in 2023 to RMB 10.5 million in 2024[54]. - The gross profit margin for 2024 was -17.3%, compared to -12.1% in 2023[97]. - The net profit margin for 2024 was -124.9%, worsening from -79.2% in 2023[97]. Research and Development - The group has established a three-tier R&D system focusing on national-level research projects, international cooperation, and clinical trials, contributing to the development of precision medical equipment[31]. - The group has received recognition for its international research capabilities, with a joint project with the Mayo Clinic being approved by the U.S. National Institutes of Health[32]. - The AI business is leveraging high-quality medical data to train tumor models focused on proton therapy, aiming to provide precise information for patients and doctors[36]. - The group is focusing on tumor diagnosis and rehabilitation management, deepening collaboration with equipment manufacturers for integrated AI diagnostic systems[37]. - Research and development expenses decreased by 14.4% from RMB 36.4 million for the year ended December 31, 2023, to RMB 31.2 million for the year ending December 31, 2024, mainly due to reduced costs associated with software system development[62]. Corporate Governance and Management - The company has a strong governance structure with independent directors providing oversight and independent opinions[117]. - The company has a diverse board with members having extensive backgrounds in finance and management[119]. - The company is committed to maintaining compliance with the Company Law of the People's Republic of China regarding its supervisory board[118]. - The supervisory board consists of three supervisors, including one employee representative supervisor, with a term of three years[118]. - The company has established a remuneration and assessment committee to review and propose recommendations regarding the remuneration of directors, supervisors, and senior management[161]. - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance and recommended approval to the board[194]. Social Responsibility and Community Engagement - The group has established a charity fund to support economically disadvantaged cancer patients, enhancing its social responsibility[39]. - The group made charitable donations totaling approximately RMB 210,000 for the year ending December 31, 2024[198]. - The company is committed to ongoing communication with regulatory bodies regarding evolving ESG-related regulations[165]. Shareholder Information and Capital Structure - Major shareholders include Ascendium Group Limited, holding 205,607,968 domestic shares (28.70%) and 96,518,100 H shares (13.47%) of the company[173]. - The company has a significant concentration of ownership, with several entities holding over 10% of total equity[174][175]. - The report indicates a diverse range of shareholders, including both domestic and H-share investors[174][175]. - The overall equity structure suggests potential for strategic partnerships and market expansion opportunities[174][175][176]. - The company holds nine low-risk financial products with a total fair value of RMB 207.2 million as of June 30, 2024, which have since been fully redeemed and settled[185]. Future Plans and Investments - The company plans to fully utilize the net proceeds from the global offering by December 31, 2025, subject to business needs and market conditions[184]. - The company is undertaking large-scale hospital construction projects, which require significant operational and financial resources[135]. - There are no detailed future plans for significant investments or capital assets as of December 31, 2024[86].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 建議選舉第四屆監事會監事 美中嘉和醫學技術發展集團股份有限公司（「本公司」）謹此宣佈，鑒於第三屆監事 會（「監事會」）任期即將屆滿，根據《中華人民共和國公司法》及本公司組織章程細 則的有關規定，監事會擬提名以下人士為第四屆監事會股東代表監事（「監事」）。 建議股東代表監事 建議 滕勝春先生 重選為股東代表監事 于越先生 重選為股東代表監事 根據本公司組織章程細則，建議選舉第四屆監事會股東代表監事須經本公司股東 （「股東」）於股東大會上批准。一份載有（其中包括）有關第四屆監事會候任股東代 表監事詳情的通函將於適當時候刊發及╱或寄發予股東。 經本公司職工代表大會選舉，本公司第三屆監事會職工代表監事蔣瓅女士獲重選 為本公司第四屆監事會職工代表監事，與本次股東大會選出的股東代表監事組成 本公司第四屆監事會。 ...

（股份代號：2453） 建議選舉第四屆董事會董事 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事（「董事」）會（「董事 會」）謹此宣佈，鑒於第三屆董事會任期即將屆滿，根據《中華人民共和國公司法》 及本公司組織章程細則的有關規定以及董事會提名委員會（「提名委員會」）的提 名，董事會擬提名以下人士為第四屆董事會成員。 候任董事 議案 | | | | 楊建宇博士 | 重選為執行董事 | | --- | --- | | 付驍女士 | 重選為執行董事 | | 常亮先生 | 重選為執行董事 | | 王雷先生 | 重選為非執行董事 | | 宋清寳先生 | 選舉為非執行董事 | | 施波濤先生 | 重選為非執行董事 | | 李雪梅女士 | 重選為獨立非執行董事 ...

CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 於2025年4月11日（星期五）舉行的2025年臨時股東大會表決結果 美中嘉和醫學技術發展集團股份有限公司（「本公司」）已於2025年4月11日（星期 五）上午9時30分假座中國北京市朝陽區光華路7號漢威大廈東區26樓A1室舉行 2025年臨時股東大會（「臨時股東大會」）。臨時股東大會乃根據中國公司法及本公 司組織章程細則的規定舉行。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 概無股東須根據上市規則於臨時股東大會上就建議決議案放棄投票。概無股份賦 予持有人權利出席臨時股東大會但須根據上市規則第13.40條於臨時股東大會上就 建議決議案放棄投贊成票。概無股東於該通函內表明其有意於臨時股東大會上就 決議案投反對票或放棄投票。 本公司合計持300,826,238股投票權股份（佔 ...

Core Viewpoint - Meizhong Jiahhe is facing significant financial pressure in the short term, with a 27.9% year-on-year revenue decline and an increase in net losses, raising concerns about its ability to turn a profit despite the launch of proton therapy services [1][2][3]. Financial Performance - For the fiscal year 2024, Meizhong Jiahhe reported total revenue of 3.88 billion yuan, a decrease from previous years [6]. - The company's hospital business generated 2.716 billion yuan, accounting for 69.9% of total revenue, down 15.1% year-on-year [3]. - Revenue from medical equipment, software, and related services was 1.167 billion yuan, making up 30.1% of total revenue, with a significant decline of 46.6% [3]. - The net loss expanded from 4.26 billion yuan in 2023 to 4.85 billion yuan in 2024, marking a 13.7% increase [3]. Business Operations - Meizhong Jiahhe operates four self-owned medical institutions primarily located in Guangzhou and Shanghai, covering the Guangdong-Hong Kong-Macao Greater Bay Area and the Yangtze River Delta [3]. - The company has been adjusting its internal business structure, focusing on high-margin departments while reducing low-margin ones, which has impacted revenue [4]. Proton Therapy Development - The Guangzhou Taihe Cancer Hospital's proton center is set to officially open in December 2024, with expectations to treat over 2,000 patients annually and generate more than 600 million yuan in revenue [5]. - Proton therapy has been operational since its launch, treating nearly 100 patients, with a treatment fee of approximately 295,000 yuan, primarily funded through self-pay and commercial insurance [7]. Market Position and Future Outlook - The management believes that the demand for high-end cancer treatment will exceed supply, especially given the company's strategic positioning in key regions [8]. - Plans are underway to establish specialized hospitals in Shanghai and Shijiazhuang, with the latter expected to open in the second half of 2026 [7].

Summary of the Conference Call for Meizhong Jiahe Company Overview - Meizhong Jiahe focuses on the oncology specialty field, providing high-end cancer medical services as a beneficial supplement to the public healthcare system. The company was established in 2008 and aims to build high-end oncology hospitals in first-tier cities to serve patients nationwide [3][4]. Core Business and Collaborations - The company collaborates with top U.S. cancer hospitals, including MD Anderson Cancer Center and Mayo Clinic, to introduce advanced treatment technologies in China [3]. - The business is divided into hospital services targeting C-end patients and a light-asset model empowering medical institutions in lower-tier cities [3]. Financial Performance and Projections - In 2024, Guangzhou Taihe Cancer Hospital is expected to generate approximately 120 million yuan in revenue, with a gross margin adjusted to -44% [3][9]. - The Shanghai outpatient department is projected to achieve medical revenue of around 82 million yuan in 2024, while the imaging center's revenue is expected to remain stable between 63 million and 64 million yuan [3][10]. - The company anticipates that by 2025, revenue from the Guangzhou hospital will exceed 300 million yuan, with total revenue not less than 500 million yuan, and positive cash flow [3][15]. Treatment Innovations - The Guangzhou Taihe Cancer Hospital's self-treatment center, which opened in December 2024, offers proton therapy, a cutting-edge radiation treatment that has already served dozens of patients by February 2025 [5][13]. - Proton therapy is highlighted for its advantages in improving cure rates and quality of life for patients with various types of tumors [5]. International Cooperation and Research - Meizhong Jiahe actively engages in international collaborations, including academic conferences and research projects, and has been selected for national high-end medical equipment promotion projects [6][8]. - The company has established partnerships with over 20 major domestic insurance companies to enhance patient access to high-end medical services [19][20]. Market Demand and Competitive Landscape - The domestic proton therapy market is characterized by high demand that exceeds supply, with an estimated 450,000 new cancer patients annually, of which 2% belong to the mid-to-high-end demographic willing to pay for advanced treatments [18]. - Currently, there are only 10 operational proton centers in China, with expectations to reach 20 within five years and 30 within ten years, indicating a significant growth opportunity for Meizhong Jiahe [18]. Challenges and Strategic Adjustments - The company has faced challenges due to tightened medical insurance policies, leading to adjustments in its business structure and a focus on high-margin departments [11][21]. - Management expenses are projected to be controlled at around 20%, with sales expenses also kept within 20% for new hospital operations [12]. Future Outlook - The company aims to leverage its unique position in the high-end oncology market to attract more patients and improve financial performance in 2025, which is seen as a pivotal year for growth [22][23]. - Efforts will be made to enhance brand recognition for high-end cancer treatment services, particularly through the use of proton therapy equipment [23].

Core Viewpoint - Meizhong Jiahe (02453.HK), the first high-end oncology medical service listed company in China, reported a total revenue of 388 million yuan for the fiscal year 2024, a decrease of 27.9% year-on-year, while gross profit increased by 3.3% to 67 million yuan. The adjusted net loss was 444 million yuan, an increase of 5.5% year-on-year. The company is expected to see a turnaround in performance in 2025, driven by the launch of proton therapy, an advanced chemotherapy technology [1][2][3]. Group 1: Financial Performance - In 2024, Meizhong Jiahe achieved total revenue of 388 million yuan, down 27.9% year-on-year [1] - Gross profit for the year was 67 million yuan, reflecting a 3.3% increase [1] - The adjusted net loss was 444 million yuan, which is a 5.5% increase compared to the previous year [1] Group 2: Proton Therapy Development - Meizhong Jiahe has launched the first proton therapy center in South China, with clinical operations starting on December 16, 2024, and has seen a growing number of patients [2] - The proton therapy center is expected to have an annual patient capacity of 2,000, with projected annual revenue exceeding 600 million yuan based on treatment costs of approximately 300,000 yuan per course [3] - The high initial costs and long construction periods for proton therapy centers create a significant barrier to entry, limiting competition and enhancing patient attraction for Meizhong Jiahe [3] Group 3: AI and Technology Integration - The company has developed a light asset business model utilizing cloud computing and has seen success with its AI and imaging business, particularly in the context of the recent boom in AI technology [4][5] - Meizhong Jiahe has established a core product matrix in AI diagnostics, aiming to empower grassroots medical institutions and enhance the distribution of quality medical resources [5] - The company is constructing China's first tumor treatment vertical model based on proton therapy, which is expected to increase the value of its AI diagnostic business [5] Group 4: Strategic Positioning - Meizhong Jiahe is the only non-public institution involved in setting multiple radiation therapy industry standards in China and has established strategic partnerships with MD Anderson and Mayo Clinic [6] - The unmet clinical demand in China's high-end medical service market, combined with the patient influx expected from the proton therapy center, positions Meizhong Jiahe as a potential standout in the medical services sector [6]

Financial Performance - The company's revenue decreased by 27.9% from RMB 538.7 million for the year ended December 31, 2023, to RMB 388.3 million for the year ended December 31, 2024[6]. - The gross loss increased by 3.3% from RMB 65.1 million for the year ended December 31, 2023, to RMB 67.2 million for the year ended December 31, 2024[6]. - The net loss increased by 13.7% from RMB 426.4 million for the year ended December 31, 2023, to RMB 484.8 million for the year ended December 31, 2024[6]. - The adjusted net loss (non-HKFRS measure) increased by 5.5% from RMB 420.6 million for the year ended December 31, 2023, to RMB 443.9 million for the year ended December 31, 2024[6]. - The total revenue for 2024 is RMB 388.3 million, a decrease of 28% from RMB 538.7 million in 2023[25]. - Revenue from hospital business decreased to RMB 271.6 million in 2024 from RMB 320.0 million in 2023, representing a decline of 15%[25]. - The company reported a loss attributable to owners of the company of RMB 443.2 million in 2024, compared to a loss of RMB 373.1 million in 2023[29]. - The gross profit margin for the year ended December 31, 2024, was (17.3)%, compared to (12.1)% for the year ended December 31, 2023[106]. - The net profit margin for the year ended December 31, 2024, was (124.9)%, compared to (79.2)% for the year ended December 31, 2023[106]. Assets and Liabilities - The total assets less current liabilities increased from RMB 4,031.9 million in 2023 to RMB 4,770.7 million in 2024[8]. - The company's cash and cash equivalents increased from RMB 40.6 million in 2023 to RMB 204.5 million in 2024[8]. - The total equity increased from RMB 1,869.2 million in 2023 to RMB 1,900.8 million in 2024[9]. - The group recorded a loss of RMB 484.8 million for the year ending December 31, 2024, with a net current liability of RMB 422.2 million[22]. - As of December 31, 2024, the financial assets measured at fair value through profit or loss amount to RMB 132.6 million, which can be converted to cash at any time when needed[24]. - As of December 31, 2024, total bank borrowings amounted to RMB 1,479.9 million, an increase from RMB 1,051.9 million in 2023, with most secured by the issued share capital of subsidiaries and certain medical imaging equipment[96]. - As of December 31, 2024, the company's current liabilities net worth was RMB 422.2 million, a decrease from RMB 844.7 million as of December 31, 2023, mainly due to increases in receivables from related parties and cash and cash equivalents[98]. - The asset-liability ratio was 67.8%, an increase from 64.3% as of December 31, 2023[106]. Cash Flow - Operating cash flow used was RMB 186.0 million for the year ended December 31, 2024, compared to cash flow generated of RMB 201.9 million for the year ended December 31, 2023, mainly due to a decrease in overall revenue[86]. - For the year ended December 31, 2024, the net cash used in investing activities was RMB 668.0 million, an increase of RMB 409.4 million compared to RMB 182.3 million for the year ended December 31, 2023, primarily due to purchases of properties, plants, and equipment, investments in joint ventures, and acquisitions of financial assets at fair value through profit or loss[88]. - The net cash generated from financing activities for the year ended December 31, 2024, was RMB 1,018.0 million, compared to a net cash used of RMB 105.4 million for the year ended December 31, 2023, mainly due to proceeds from bank and other borrowings and issuance of new shares[89]. Operational Developments - The proton therapy center at Guangzhou Taihe Tumor Hospital commenced full clinical operations on December 16, 2024, expected to enhance sales performance[24]. - The group has established a proton therapy center at Guangzhou Taihe Tumor Hospital, which is the first of its kind in South China, aiming to enhance revenue and profit in the high-end medical service market[33]. - The Shanghai Taihe Cheng Tumor Hospital is under construction with a total building area of nearly 160,000 square meters, designed to provide advanced precision radiotherapy services[33]. - The group is expanding its services to Southeast Asia, targeting high-incidence tumors like nasopharyngeal cancer, and is developing customized treatment packages in collaboration with regional insurance institutions[37]. - The group has launched a "Proton Therapy Special Insurance" in partnership with well-known insurance companies, increasing accessibility for middle-class patients to advanced international treatment technologies[38]. - The group has implemented a light asset business model to provide medical equipment, software, and related services, particularly targeting healthcare institutions in second and third-tier cities[34]. - The group has established a comprehensive network involving medical institutions, research organizations, and equipment manufacturers to support continuous business growth[34]. Cost Management - The company has strengthened cost control measures to reduce administrative costs and deferred capital expenditures[24]. - Sales cost decreased by 24.5% from RMB 603.7 million for the year ended December 31, 2023, to RMB 455.6 million for the year ended December 31, 2024[60]. - Employee benefits expenses decreased by 31.6% from RMB 164.9 million to RMB 112.8 million, attributed to improved human resource efficiency[64]. - Administrative expenses increased by 9.0% from RMB 191.2 million to RMB 210.5 million, mainly due to increased consulting fees recognized in 2024[69]. - R&D expenses decreased by 14.4% from RMB 36.4 million to RMB 31.2 million, primarily due to reduced costs related to software system development[70]. Future Outlook - The group anticipates adopting all newly issued accounting standards in the first period following their effective dates[16]. - The group is currently evaluating the impact of new accounting standards and amendments on its financial reporting[18]. - The group aims to optimize regional layout by focusing on economically developed urban clusters and enhancing market penetration in second and third-tier cities[51]. - The introduction of advanced technologies such as proton therapy and immunotherapy is expected to upgrade service capabilities and provide one-stop treatment services[52]. - The group plans to enhance patient experience through the development of follow-up systems and integrated service resources[53]. Corporate Governance - The company has complied with the corporate governance code throughout the reporting period[116]. - The audit committee, composed of three independent non-executive directors, reviewed the annual performance and recommended approval to the board[118]. - The company will not declare any final dividend for the year ending December 31, 2024[124]. - An extraordinary general meeting is proposed to be held on April 11, 2025, for shareholders to consider and approve the provision of guarantees[122]. - The annual general meeting is scheduled for May 27, 2025, with a record date for voting eligibility set for May 27, 2025[123][125].

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 臨時股東大會通告 茲通告美中嘉和醫學技術發展集團股份有限公司（「本公司」）謹訂於2025年4月11 日（星期五）上午9時30分假座中國北京市朝陽區光華路7號漢威大廈東區26樓A1室舉 行臨時股東大會（「臨時股東大會」），以考慮及酌情通過以下決議案： 除另有指明外，本通告所用詞彙與日期為2025年3月20日的通函所界定者具有相 同涵義。 特別決議案 1. 審議及批准關於2025年度向金融機構申請綜合授信額度暨提供擔保的議案。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 香港，2025年3月20日 附註： – 1 – 1. 有關於臨時股東大會上批准之決議案的詳情，請參閱日期為2025年3月20日的通函（ ...